Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of atopic dermatitis (AD). AD (eczema) is a chronic inflammatory skin disease often linked to depression and a decreased quality…
Read More
Genome BC is ]launching a rapid response funding program to invest in promising research and innovation projects with the real potential to address urgent challenges related to the COVID-19 pandemic. The initiative is using a specifically designed process for reviewing applications and providing funds for approved projects within days. This rapid response will enable researchers and innovators to launch projects…
Read More
On March 21, 2020, the virology laboratory at St. Paul’s Hospital started using a new high throughput, fully automated COVID-19 testing method – a first in Canada. “Testing is the key to COVID-19 diagnostics (for patient care) and surveillance (for public health),” says Dr. Marc Romney. “And high-volume testing capacity is critical in our fight to contain and control the spread…
Read More
Canada’s largest biotechnology company, Vancouver’s STEMCELL Technologies, has been making significant contributions to the fight against COVID-19. Human tissue culture systems developed by STEMCELL were used by researchers at China’s Centre for Disease Control (CDC) to grow lung airway cells that could successfully propagate the novel coronavirus SARS-CoV-2. Scientists were then able to isolate the virus, obtain the viral gene sequence, and quickly make…
Read More

SFU Student’s Honours Project Leads to BC-CfE Job

As a curious, keen problem solver who works to better understand HIV molecular virology, Hanwei Sudderuddin’s experiences with the Faculty of Health Sciences (FHS) have prepared him for his current work with the BC Centre for Excellence in HIV/AIDS (BC-CfE). After becoming intrigued with FHS professor Zabrina Brumme’s research upon listening to her speak as a guest for his FHS immunology class,…
Read More
Canada’s strength in regenerative medicine (RM) and cell and gene therapies is a result of efforts that take place from sea to shining sea. Western Canada’s growing RM community significantly increases Canada’s competitiveness on the global playing field through its leading-edge research, advanced commercialization abilities, and excellent education and training programs. Prowess in research The region’s renowned researchers aim to…
Read More
For people with mental health conditions, finding a medication that works without causing severe side effects is often a matter of trial-and-error. This can contribute to a lower adherence to treatment regimens and poorer health, as well as increased costs to the health care system. Pharmacogenomics can improve a person’s health by helping them know ahead of time whether a…
Read More
After the success of last year’s inaugural Canadian Blood Services’ Lay Science Writing Competition, we couldn’t wait to do it again! The Centre for Innovation was delighted to once again partner with science communication and research leaders Science Borealis and the Centre for Blood Research at the University of British Columbia to host this competition. This time around, we asked our research trainees to send us “Stories…
Read More
Simon Fraser University researchers will use their pioneering imaging technology—called Mango, for its bright colour— to develop coronavirus testing kits. They’re among a small set of Canadian researchers who responded to the rapid funding opportunity recently announced by the Canadian Institutes of Health Research (CIHR) to help address COVID-19. SFU researchers Lena Dolgosheina, a post-doctoral fellow and Peter Unrau, a professor of molecular…
Read More
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung…
Read More